FULL-TEXT ARTICLE HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment. Sarrazin C, Manns M, Calleja JL,et al PLoS One. 2016 Dec 28;11(12):e0168544. Paper Effect of D168V mutation in NS3/4A HCV protease on susceptibilities of faldaprevir and danoprevir. Meeprasert A, Hannongbua S, Kungwan N, Rungrotmongkol T. Mol Biosyst. 2016 Oct 12. Abstract Safety and efficacy of faldaprevir in combination with pegylated interferon alfa-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection. Nishiguchi S, Urano Y, Suzaki K, Taniguchi A, et al Hepatol Res. 2016 May 6. Abstract Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. Zeuzem S, Mantry P, Soriano V,  et al Eur J Gastroenterol Hepatol. 2016 Apr 29 Abstract Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. Jensen DM, Asselah T, Dieterich D,  et al Ann Hepatol. 2016 May-Jun, 2016;15(3):333-349. Abstract Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants. Wu J, Gießmann T, Lang B, et al J Pharm Pharmacol. 2016 Mar 28. Abstract FULL-TEXT ARTICLE ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. Asselah T, Zeuzem S, Soriano V,  et al PLoS One. 2015 Dec 9;10(12):e0144004. Paper

Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of HCV Genotype-1 Following Treatment with Faldaprevir plus Pegylated Interferon Alfa-2a and Ribavirin in Phase 2 and Phase 3 Studies.
Berger KL, Scherer J, Ranga M, et al
Antimicrob Agents Chemother. 2015 Jul 20.
Abstract

Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
Dieterich D, Nelson M, Soriano V,  et al
AIDS. 2015 Mar 13;29(5):571-581.
Abstract

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
Ferenci P, Asselah T, Foster GR,  et al
J Hepatol. 2015 Jan 2. pii: S0168-8278(14)00953-2
Abstract

Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-naïve Patients with Chronic Hepatitis C and Advanced Liver Fibrosis/Cirrhosis.
Zeuzem S, Soriano V, Asselah T,  et al
Antimicrob Agents Chemother. 2014 Dec 15. pii: AAC.04383-14
Abstract

Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers.
Joseph D, Rose P, Strelkowa N,  et al  
J Clin Pharmacol. 2014 Oct 28.
Abstract

Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz and tenofovir.
Sabo JP, Kort J, Ballow C,  et al.
Clin Infect Dis. 2014 Aug 4.
Abstract

SILEN-C3: A Phase 2 Randomized Trial with Faldaprevir plus PegIFN/Ribavirin in Treatment-naive HCV Genotype-1-infected Patients.
Dieterich D, Asselah T, Guyader D,  et al
Antimicrob Agents Chemother. 2014 Apr 7.
Abstract

Generating an In Vitro-In Vivo Correlation for Metabolism and Liver Enrichment of a Hepatitis C Virus Drug, Faldaprevir, Using a Rat Hepatocyte Model (HepatoPac).
Ramsden D, Tweedie DJ, et al
Drug Metab Dispos. 2014 Mar;42(3):407-14.
Abstract

Enzyme-Transporter Interplay in the Formation and Clearance of Abundant Metabolites of Faldaprevir Found in Excreta but not in Circulation.
Li Y, Zhou J, Ramsden D, T et al
Drug Metab Dispos. 2014 Mar;42(3):384-93.
Abstract

FULL-TEXT ARTICLE
Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
Berger KL, Triki I, Cartier M, et al
Antimicrob Agents Chemother. 2014 Feb;58(2):698-705.
Paper

Bridging In Vitro and In Vivo Metabolism and Transport of Faldaprevir in Human Using a Novel Co-cultured Human Hepatocyte System, Hepatopac™
Ramsden D, Tweedie DJ, Chan TS,  et al
Drug Metab Dispos. 2013 Dec 23
Abstract

Baseline HCV NS3 Polymorphisms and their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor Faldaprevir.
Berger KL, Triki I, Cartier M, et al
Antimicrob Agents Chemother. 2013 Nov 11
Abstract

Viral Resistance in Hepatitis C Genotype-1 Infected Patients Receiving the NS3 Protease Inhibitor Faldaprevir (BI 201335) in a Phase 1b Multiple Rising-dose Study.
Berger KL, Lagacé L, Triki I,  et al
Antimicrob Agents Chemother. 2013 Jul 22
Abstract

Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype-1 HCV: SILEN-C1 trial.
Sulkowski MS, Asselah T, Lalezari J,  et al
Hepatology. 2013 Jan 28.
Abstract

FULL-TEXT ARTICLE n vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Lagacé L, White PW, Bousquet C,  et al Antimicrob Agents Chemother. 2012 Jan;56(1):569-72 Paper

Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor. Duan J, Yong CL, Garneau M, Amad M,  et al Xenobiotica. 2012 Feb;42(2):164-72 Abstract

Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Zeuzem S, Asselah T, Angus P,  et al Gastroenterology. 2011 Dec;141(6):2047-55; Abstract

Combined X-ray, NMR, and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3-NS4A protease inhibitor BI 201335. Lemke CT, Goudreau N, Zhao S,  et al J Biol Chem. 2011 Apr 1;286(13):11434-43 Abstract

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. Manns MP, Bourlière M, Benhamou Y, et al J Hepatol. 2011 Jun;54(6):1114-22. Abstract

Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. White PW, Llinàs-Brunet M,  et al Antimicrob Agents Chemother. 2010 Nov;54(11):4611-8 Abstract

Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335). Llinàs-Brunet M, Bailey MD, Goudreau N,  et al J Med Chem. 2010 Sep 9;53(17):6466-76 Abstract